Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy

Yusha Wang1,2†, Lei Zhang3†, Yun Bai4, Li Wang2* and Xuelei Ma1*

1Division of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, 2Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China, 3Department of Obstetrics and Gynecology, Chengdu First People’s Hospital and Chengdu Integrated Traditional Chinese Medicine (TCM) and Western Medicine Hospital, Chengdu, China, 4West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China

Epithelial ovarian cancer (EOC) ranks as the second most common cause of gynecologic cancer death. The conventional treatment for patients with EOC is postoperative therapy along with platinum chemotherapy. However, a more efficient treatment regimen is of great need for these patients diagnosed with advanced disease (FIGO stages III–IV), whose survival is approximately 29%. Immunotherapy seems to be an encouraging therapeutic strategy for EOC. Given the crucial role in the complicated interactions between tumor cells and other cells, the tumor microenvironment (TME) influences the response to immunotherapy. In this review, we discuss feasible strategies for EOC immunotherapy by exploiting the reciprocity of cancer cells and the constituents of the TME.

KEYWORDS

tumor microenvironment, immunotherapy, immune cells, stromal cells, combination therapy
1 Introduction

Epithelial ovarian cancer (EOC) recognized by its high occurrence and poor prognosis (1), ranks as the second most common cause of gynecologic cancer death (2). The conventional treatment for EOC patients is postoperative therapy along with platinum chemotherapy (3). However, survival is dismal since over two-thirds of patients are diagnosed with advanced disease (FIGO stages III–IV) (4), and the survival rate for advanced stages is about 29% (5). Thus, a more effective treatment is of great need for these patients. Currently, immunotherapy is an encouraging treatment for various cancers (6). Immunotherapy agents are used to activate effector and cytotoxic T cells that respond to cancer cells through natural mechanisms, many of which are suppressed during cancer progression (7). Poor response to immunotherapy in ovarian tumors was associated with low expression of programmed cell death ligand 1 (PD-L1) (8). Therefore, it is urgent to explore the cells in the TME and their effects on the response of immune checkpoint inhibitors (ICIs).

The tumor microenvironment (TME), which is made up of vessels, immune infiltration and extracellular matrix (ECM), promotes cancer growth, invasion and metastasis (9). Understanding the interplay between cancer cells and various immune cells in the TME such as T lymphocytes, dendritic cells (DCs), tumor associated macrophages (TAMs) and natural killer (NK) cells, could explain the pathogenesis and explore novel therapies for EOC (10)(11). Immune editing, defined as the dual function of the immune system, can suppress and/or promote tumor growth (12). Studying the dual function of immune cells in the TME can suppress the key pathways that inhibit antitumor responses, and promising therapies will be discovered (13). PD-1 and CTLA-4 expressed on T cells are the basis of immune checkpoint immunotherapy (14). Additionally, immunosuppressive molecules in the TME such as indoleamine-2,3-dioxygenase (IDO), interleukin-10 (IL-10) and prostaglandin E2 (PGE2), can also be targets of immunotherapies (15).

In this review, the effect of the TME in immunotherapies and progress in EOC immunotherapy will be discussed.

2 Tumor microenvironment

2.1 Suppressive immune cells

2.1.1 Regulatory T cells

T-lymphocytes in the TME contain tumor infiltrating lymphocytes (TILs) and regulatory T cells (Tregs). Tregs have been shown to weaken antitumor immunity indicating poor prognosis in patients with EOC (16). Studies have revealed that increases in tumor Treg cells represent a low survival rate of EOC (16), while other studies show their association with a pleasing clinical outcome biomarker in colorectal cancer (17). Immunosuppressive mechanisms regulated by Tregs leading to immunological tolerance and ignorance of cancer are as follows: 1) releasing soluble or membranous repressive cytokines such as interleukin-10 (IL-10), interleukin-35 (IL-35) and transforming growth factor-β (TGF-β), which can kill effector T cells (18), 2) high expression of granzymes and perforin mediates the cytolsis of NK cells and cytotoxic CD8+ T cells (19), 3) interfering with effector T cell metabolism by reducing IL-2, which is competitively consumed by T cells, and increasing adenosine which is an inhibitory molecule (20), 4) inducing DC tolerance by expressing CTLA-4 and ligands CD80 and/or CD86 on DCs that can generate immunosuppressive tryptophan metabolites, lymphocyte activation gene 3 (LAG3) molecules can suppress MHC II molecules on DCs (21). In view of the key immunosuppressive effect of Tregs, several agents have been explored that directly target markers such as CTLA-4 and IL-2 (20, 22).

2.1.2 Tumor associated macrophages

Tumor-associated macrophages (TAMs) are recruited from monocytes in blood and resident peritoneal macrophages, and these are major infiltrating immune cells in the TME (23). Given the important heterogeneity and plasticity, TAMs contain two groups: anti-tumorigenic M1 type and pro-tumorigenic M2 type (24). In the TME, the most pro-tumorigenic M2-like phenotype (25) is critical for cancer angiogenesis, invasion and metastasis through different kinds of cytokines, chemokines, growth factors, and proteases (26, 27). Vascular endothelial growth factor A (VEGF-A), a pro-angiogenetic chemokine and protease secreted by TAMs promotes tumor angiogenesis (26, 28). By producing epidermal growth factor (EGF), TAMs promote cancer cell proliferation (29). Moreover, TAMs exhibit immunosuppressive effects through secreting IL-10, TGF-β, CCL2 and arginase (30, 31). Current studies targeting TAMs mainly include: 1) suppressing M2-like TAMs via inhibiting the recruitment of TAMs and exhausting TAMs 2) activating M1-like TAMs by strengthening the repolarization of M2 macrophages into M1 macrophages (32, 33). For inhibition of the recruitment of TAMs, the CCL2/CCR2 axis barricade which is has been found to be helpful in a mouse ovarian cancer model (34), and disrupting the CXCL12/CXCR4 axis which prolongs the survival of a tumor mouse model (35) seem to be an encouraging therapy. The decrease in TAMs caused by inhibiting the CSF-1/CSF-1R pathway has been proven to strengthen the tumor suppressive effect of docetaxel (36). In EOC, trabectedin can effectively deplete macrophages by inducing apoptosis of macrophages and thus play an antitumor role in ovarian cancer (37). Paclitaxel treats ovarian cancer by reprogramming the M2 to the M1 phenotype through...
TLR4 in gene expression analysis (38). Furthermore, another macrophage-directed therapy targets PD-L1 on TAMs which is involved in tumor immune escape mechanisms (39, 40).

2.1.3 Myeloid-derived suppressor cells

Myeloid-derived suppressor cells (MDSCs) are a subpopulation of immunoregulatory immature myeloid cells that increase in multiple pathologic situations (41). MDSCs have been implicated in suppressing T cells and impacting other cells in the TME (42). The mechanisms of suppressing T cells include the following: 1) accelerating the depletion of T cell essential amino acids such as L-cysteine, L-arginine and L-tryptophan which are critical for T cell activity (43–45). 2) expressing PD-L1 interacting with PD-1 on T cells to suppress the antitumor effect of T cells and thus promote immune evasion (46). 3) producing ROS and NO which are toxic to T cells (47). Moreover, MDSCs boost the activation of Tregs via IL-10 and TGFβ in the need of CD40 (48, 49). MDSCs can be targeted by various strategies: 1) reduction of MDSCs, 2) inhibition of the recruitment of MDSCs, 3) suppression of MDSC function and 4) induction of MDSCs to differentiate into non-suppressive cells (50). Thus, immunotherapies in combination with targeting MDSCs could be a major strategy. Phosphodiesterase-5 (PDE-5) inhibitors targeting arginase 1 (ARG1) and iNOS restabilize the immunosuppressive response of T cells (51). Synthetic triterpenoids activate the Nrf2 gene which modulates antioxidant enzymes and nitroaspirin, inhibiting iNOS and ROS production and thus relieving the oxidative stress caused by MDSCs (52, 53). Furthermore, STAT3 inhibitors combined with immune checkpoint blockade have been shown to be beneficial in lymphoma (54). In addition, blocking COX-2 which is correlated with the expression of ARG1 can also be a promising approach to attenuate MDSC function (55). A schematic illustration of how suppressive immune cells affect the antitumor immune response in the TME is shown in Figure 1.

2.2 Activated immune cells

2.2.1 T lymphocytes

TILs contain CD8+ T and CD4+ T lymphocytes, especially CD8+ TILs which represent a good prognosis of EOC (56). CD8+ T cells recognize and kill pathogenic infections or cancer cells through perforin and granzyme (57). In addition to destroying cancer cells directly, CD8+ T cells suppress tumor vascularization via secreting IFN-γ which suppresses the development of cancer. Emerging evidence has revealed that CD8+ T cells in the TME are often beneficial to survival in ovarian cancer patients (58). Furthermore, CD4+ T cells are divided into different subtypes which include T helper 1 (Th1) cells, a group of cells that provide cytokines such as IL-2 and IFN-γ to support the antitumor effect of CD8+ T cells (59). Moreover, high expression of CCL5 released by CD4+ T cells benefits the activation of DCs and thus induces an antitumor response (60). Hence, increases in Th1 cells within the TME are believed to have significant outcomes in a variety of cancers (61). As mentioned above, not all T cells function as antitumor effectors such as Tregs and Th17 cells. Thus, immunotherapies targeting the main impaired antitumor T effector cells are considered.

**FIGURE 1**

Immunosuppressive cells in the TME. Immune suppressive cells mainly contain Tregs, TAMs and MDSCs. Tregs restrain antitumor effecter T cells including i) secretion of repressive cytokines such as IL-10, IL-35 and TGF-β; ii) induction of cytolyis via releasing granzymes and perforins; iii) metabolic disturbance through adenosine production. Also, Tregs induce antigen presenting cell dysfunction for a tolerant phenotype. TAMs can i) secrete EGF and MMPs to promote tumor progression; ii) produce VEGF to aid in tumor angiogenesis; iii) secrete IL-10 and TGF-β to induce Treg activation. MDSCs suppress T cells through i) secretion of IL-10 and TGF-β which induce Tregs; ii) production of NO and ROS which induce cytolyis and inhibit T cell activation; iii) depletion of essential amino acids which play a crucial role in T cell activation and proliferation.
optimistic therapeutic approaches (62, 63). Recently, major advances have been made in developing PD-1 therapy which can potentiate the efficacy of CD8+ T cell based immunotherapy (64). T cells express PD-1 while other cells such as Tregs, TAMs, and cancer cells express PD-L1. Consequently, blockade targeting PD-1 or PD-L1 can suppress activation of T cell and breakdown immune tolerance and thus potentially mobilize immunity in tumors (65, 66).

2.2.2 Natural killer cells

NK cells are the most efficient antineoplastic effectors and do not need any prior sensitization or HLA-independent tumor target recognition (67, 68). NK cells encompass two main populations with CD56bright/CD16+ functioning to produce IFN-γ and TNF-α cytokines, while CD56dim/CD16+ killing tumor cells directly via releasing perforin/granzyme or through TRAIL pathways (69). However, NK cells usually exhibit dysfunction in the TME, such as reduced proliferation, decreased secretion of cytotoxic molecules and abnormal expression of immune checkpoints (70). Studies have revealed that PD-L1 on tumor cells can inhibit PD-1 expression on NK cells, thereby promoting immune escape from cancer (71). A series of molecules such as IDO and PGE2 secreted by fibroblasts were shown to suppress the expression of the activating receptor NKG2D and thus mediate immune escape (72). Several immunotherapeutic strategies based on NK cells are currently being explored including adaptive NK cells, cytokines, antibodies and ICIs (68). Remarkably, adaptive NK cell therapy induced by various cytokines exhibits enhanced antitumor effects in ovarian cancer (73). Currently, therapy based on cytokines such as IL-2 and IL-15 is shown to vigorously increase NK cells (74, 75). Although antibody-based immunotherapy is not the gold standard treatment for ovarian cancer patients, antigens on tumor cells including NY-ESO-1 and MUC1 have attracted great attention (76). Furthermore, evidence has revealed that PD-1 and CD96/TIGIT inhibitors potentiate the tumor lysis mediated by NK cells (77).

2.2.3 Dendritic cells

DCs capture and process antigens to T cells and secrete inflammatory cytokines to induce pathogen-specific T-cell effects (78). Generally, DCs submit exogenous antigen peptides to CD4+ T cells through MHC II molecules and endogenous antigens to CD8+ T cells with MHC I molecules, and strengthen CD4+ and CD8+ T cell activity via presenting exogenous antigens (79, 80). However, the tumor microenvironment inhibits DC maturation through immunosuppressive factors including VEGF, IL-6, IL-10 and TGF-β, as well as repressive molecules including IDO (81, 82). Nevertheless, upregulating suppressive receptors such as PD-L1 and LAG3 induces T cell exhaustion thereby limiting the immune response (83). IDO produced by DCs restrains the function of NK cell and CD8+ T cell leading to an abated immune response (84). Therapeutic schemes targeting DCs have attracted great attention. Clinical studies revealed that IDO1 inhibitors combined with chemotherapy or ICIs elicit tumor regression (85). Collectively, potential DC based immune therapy seems to be an encouraging target against ovarian cancer. Furthermore, with such an effective ability for Ag presentation and T cell activation, DCs were tested as cancer vaccines that can produce "trained" DCs carrying tumor antigens and thus potentially induce strong antitumor T-cell effects (86, 87). In particular, it is well documented that DC vaccines combined with ICIs may result in synergistic effects (88, 89). A schematic illustration of how immune active cells exhibit dysfunction in the TME is shown in Figure 2.

2.3 Tumor-associated stromal cells

2.3.1 Cancer-associated fibroblasts

CAFs derived from mesenchymal stem cells are crucial components of stromal cell types (90, 91). CAFs produce proteins, paracrine cytokines and various ECMs that contribute to shaping the tumor microenvironment (92, 93). Classical growth factors secreted by CAFs include the following: 1) TGF-β regulates the interaction between cancer and stroma thereby facilitating tumor initiation and progression (94). 2) Epidermal growth factor (EGF) maintains the expression of ATC integrin α5 (ITGA5) which can promote the early peritoneal spread of HGSOC (95). 3) Hepatocyte growth factor (HGF) contributes to proliferation via the c-Met/PI3K/ Akt and GRP78 pathways (96). 4) CXCL12, IL6, and VEGFA induced by CAFs result in the epithelial-to-mesenchymal transition (EMT) which can promote peritoneal metastasis of ovarian cancer (97). 5) CAFs activate MMPs to assist in the growth, invasion, and metastasis of tumors (98). 6) Lipoma-preferred partner (LPP) which has been proven to increase the focal adhesion and stress fiber formation of ECs contributes to ovarian cancer chemoresistance (99). Therapeutic strategies targeting CAFs fall into several aspects, one of which involves TGF-β inhibitors which were shown to improve the overall survival of EOC in a mouse model with peritoneal metastasis (100). Imatinib, an inhibitor targeting PDGF-D produced by fibroblasts was found to suppress ovarian cancer cell growth (101).

2.3.2 Cancer-associated adipocytes

Cancer-associated adipocytes (CAAs) are documented to promote stromal reshaping and the invasion of cancer cells through interacting with ovarian cancer cells in the TME (102). It has been proven that metastases appear in the omentum which is made up of adipocytes in most patients with ovarian cancer (103). Adipocytes secrete various molecules such as metabolites, MMPs, enzymes and growth factors supporting tumor cell
progression (104). Furthermore, coculture studies found that CAAs boost the oxidation of cancer cells, indicating that CAAs supply energy to maintain the ovarian cancer cells proliferation (105). Additionally, CAAs produce adipokines that can promote tumor development. Among them, leptin stimulates the migration and invasion abilities of ovarian cancer cells through the JAK/Stat3, PI3K/Akt and RhoA/ROCK pathways (106). FABP4, a lipid chaperone protein is a key regulator in ovarian cancer metastasis (107). Molecules including IL-6, IL8 and TNF-α secreted by CAAs have also been proven to aid in the growth and invasion of breast tumor cells (108). Collectively, the reciprocation between CAAs and cancer cells results in the metastasis of tumor cells. Overall, therapeutic strategies specifically targeting lipid metabolism and transport such as FABP4 inhibitors in ovarian cancer are full of hope (107).

2.3.3 Endothelial cells

Endothelial cells (ECs) impact the process of cancer growth and invasion (109). Angiogenesis is known to be a process regulated by the interplay of angiogenic activators and inhibitors. During tumor progression, oxygen deficiency and accumulation of metabolic products lead to hypoxia and acidity in the TME (110). Hypoxia in the TME induces the production of hypoxia-inducible factors (HIFs), which promote pro-angiogenic factors secreted by ECs, thereby promoting angiogenesis (111). In the course of angiogenesis, factors produced by cancer cells contain VEGF, platelet derived growth factor (PDGF), fibroblast growth factor 2 (FGF-2) and angiopoietins (112). VEGF, a chemokine secreted into malignant ascites contributes to the genesis of tumor blood via signaling with VEGF receptor-2 (113). To stabilize and increase the maturation of endothelial cell channels, pericytes express PDGFR-β which can interact with PDGF-B (114). Furthermore, FGF-2 promotes the production of MMPs, collagenase and plasminogen activator resulting in vascularization (115). In addition, FGF expression has been proven to be responsible for resistance to VEGF targeted therapies (116). Angiopoietin 1 and 2 (Ang1/2) has been found to promote the proliferation and survival of ECs via binding to the Tie-2 receptor (117). Thus, considerable attention is being paid to exploring therapeutic strategies to block the angiogenic signaling pathway. Bevacizumab as the most studied anti-VEGF monoclonal antibody has been demonstrated to positively increase PFS with cisplatin-based chemotherapy in several randomized phase III trials and has been recognized as the standard treatment in EOC (118, 119). Tyrosine kinase inhibitors (TKIs) such as pazopanib and cediranib are promising VEGFR targeting agents for ovarian cancer patients (120, 121). Trebananib, an inhibitor that targets non-VEGF signaling has meaningful effects on PFS when used in combination with paclitaxel in recurrent ovarian cancer through binding to Ang1/2 (122).

3 Novel combination approaches

It is obviously that ICIs have revolutionized immunotherapy and brought concrete benefits to many patients. However, the
response rate is unsatisfactory with different anti-PD-1 or PD-L1 agents since EOC is known to have a high immunosuppressive TME and low expression of PD-L1 (8). Novel combination therapies are currently evolving. Inhibitor of PD-1 in combination with CTLA-4 increased the frequency of tumor infiltration by effector T cells as well as uniquely decreased the frequency of Tregs in tumors (123). Evidence from clinical trials found that this combination blockade therapy is effective. The NRG-GY003 study showed that in recurrent epithelial ovarian cancer, nivolumab combined with ipilimumab led to an effective response rate of 31.4% while nivolumab alone is 12.2%. In addition, the mPFS was 2 months in the monotherapy group and 3.9 months in the combination treatment group (124). Combining nivolumab with ipilimumab produced higher response rates and longer PFS in EOC than nivolumab alone, but is still limited, so more combination clinical studies such as NCT02834013 and NCT03508570 are underway.

In a mouse model of intraperitoneal ovarian cancer, compared with single drug therapy of AMD3100 (CXCR4 antagonist) and α-PD-1, the antitumor efficacy of combined therapy in inhibiting tumor growth and prolonging the survival time of mice was significantly improved (35). This provides strong preclinical evidence for ovarian cancer combination therapy, but to date, no clinical trials related to ovarian cancer have been carried out. It is worth noting that in a phase IIa trial, disease control with BL8040 plus pembrolizumab was 34.5% in 29 patients. 22 patients were treated with BL8040 plus pembrolizumab plus chemotherapy. The results exhibited an effective response rate of 32% and a disease control rate of 77% (125). These data all suggest that the combination of CXCR4 antagonists and PD-1 inhibitors can amplify the antitumor effect of chemotherapy.

In recent years, transmembrane protein triggering receptor expressed on myeloid cells 2 (TREM2) has gained great attention in anti-PD-1 resistant therapy since its enriched expression on TAMs in EOC (126). In a model of invasive ovarian cancer in situ, anti-TREM2mAb therapy can drive effective antitumor immunity (126). This finding indicates that TREM2 is a potential immunotherapy target when ICIs are ineffective and TAMs are rich in the tumor microenvironment. A phase I clinical trial (NCT04691375) to evaluate the single drug anti-TREM2 and anti-TREM combined with pembrolizumab in solid tumors which include ovarian cancer is underway.

Evidence has shown that PD-1 blockade in combination with a VEGF-A inhibitor can potentiate antitumor efficiency via increases in CD8+ and CD4+ T cells, and decreases in MDSCs and Tregs (127, 128). In a single-arm phase 2 clinical study, 38 women with recurrent epithelial ovarian cancer were screened for intravenous treatment with nivolumab and bevacizumab. The results showed that the ORR was 28.9%, among which 40.0% were platinum sensitive patients and 16.7% were platinum resistant patients (129). These data indicate that the combining nivolumab with bevacizumab is effective and feasible in ovarian cancer patients, especially those who are sensitive to platinum.

Poly-(ADP)-ribose polymerase inhibitors (PARPi), known as synthetic lethal agents in tumors with BRCA1/BRCA2 mutations are rapidly evolving (130). Combining PARPis with PD-1/PD-L1 blockades is a promising therapy that can synthetically enhance the antitumor effect (131). A phase II clinical study of MEDIOLA found that 32 patients received olaparib combined with durvalumab, and the overall disease control rate was 81% (132). The final result of the study showed that the OS of 31 patients treated with olaparib combined with durvalumab and bevacizumab was 31.9 months compared with that of 23.2 months in the two-drug group. In addition, the DCR of the two-drug group at 56 weeks was 9.4%, and that of the three-drug group was 38.7%, which indicated that the three-drug treatment mode was superior to the two-drug treatment mode for platinum-sensitive recurrent non-gBRCA ovarian cancer patients (133). The three-drug regimen has been applied to a third-phase clinical study of first-line maintenance therapy (NCT03737643).

4 Discussion

Immune checkpoint immunotherapy has been the most prominent therapeutic strategy for successfully treating different kinds of cancers. However, the response rate in EOC is low since the immunosuppressive tumor microenvironment could limit the efficiency of ICIs. It is urgent to improve the effect of immunotherapy for EOC. Novel targets have been described and targeting approaches combined with ICs have already impacted the clinical outcomes of ovarian cancer. Targeting immune subtypes such as TAMs, Tregs, CAFs or angiogenesis could contribute to potentiating the antitumor effect of ICs. However, there are still many details to explore and discuss. In summary, the constituents within the TME should all be considered to explore novel combinations that contribute to achieving maximal benefits in EOC.

Author contributions

YW and LZ wrote the original manuscript. YB drew the figure. XM and LW corrected the original draft. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Momenimovahed Z, Tiznoobak S, Tabri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Women’s Health (2019) 11:287-99. doi: 10.2147/IJWH.S191604
2. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA: Cancer J For Clin (2019) 69 (4):3125. doi: 10.3322/caac.21559
3. Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ (Clinical Res Ed) (2020) 371:m3773. doi: 10.1136/bmj.m3773
4. Baci D, Bosi A, Gallazzi M, Rizzi M, Noonan DM, Poggi A, et al. The ovarian cancer tumor immune microenvironment (TIME) as target for therapy: A focus on innate immunity cells as therapeutic effectors. Int J Mol Sci (2020) 21(9):3125. doi: 10.3390/ijms21093125
5. Kouba S, Ouldamer L, Garcia C, Fontaine D, Chantome A, Vandier C, et al. Lipid metabolism and calcium signaling in epithelial ovarian cancer. Cell Calcium (2019) 81:38-50. doi: 10.1016/j.ceca.2019.06.002
6. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2017) 17(1):43-54. doi: 10.1038/nrrev canc.2016.5
7. Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discovery (2019) 18(3):175-96. doi: 10.1038/s41573-018-0066-z
8. Chardin L, Leary A. Immunotherapy in ovarian cancer: Thinking beyond PD-1/PD-L1. Front Oncol (2021) 11:795547. doi: 10.3389/fonc.2021.795547
9. Meurette O, Mehen P. Notch signaling in the tumor microenvironment. Cancer Cell (2018) 34(4):356-46. doi: 10.1016/j.ccell.2018.07.009
10. Pogge von Strandmann E, Reintz S, Wager U, Müller R. Tumor-host cell interactions in ovarian cancer: Pathways to therapy failure. Trends In Cancer (2017) 3(2):137-48. doi: 10.1016/j.trecan.2016.12.005
11. D’Onofrio JS, Teng MWL, Smyth MJ. Cancer immunodeserting and resistance to T cell-based immunotherapy. Nat Rev Canc (2019) 16(3):151-67. doi: 10.1038/s41573-018-0142-8
12. Schreiber RD, Old LJ, Smyth MJ. Cancer immunodetcting: integrating immunes’ roles in cancer suppression and promotion. Sci (New York NY) (2011) 331(6024):1565
13. Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest (2015) 125(9):3335-7. doi: 10.1172/JCI83971
14. Grazier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. EMBO Open (2017) 2(2):e002133. doi: 10.15252/emoop.2017.002133
15. Kanddal LF, Odunsi K, Coukos G. Immunotherapy in ovarian cancer: Are we there yet? J Clin Oncol (2019) 37(27):2468-71. doi: 10.1200/JCO.19.00508
16. Curjel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 10(9):942-9. doi: 10.1038/nm1093
17. Sakaguchi S, Mikami N, Wing JB, Lagni A, Laflavna P. Tumor-associated macrophages and myeloid-derived suppressor cells as immunosuppressive mechanism in ovarian cancer patients: Progress and challenges. Int J Immunol (2016) 36(5):372–85. doi: 10.4088/ijmm.1517.21197
18. Beltramini T, De Palma M. Biology and therapeutic targeting of tumor-associated macrophages. J Pathol (2020) 251(5):573-92. doi: 10.1002/path.5403
19. Mantovani A, Marchesi F, Malesci A, Laghi L, Allevana P. Tumor-associated macrophages as treatment targets in oncology. Nat Rev Canc (2017) 17(4):399-416. doi: 10.1038/nrrev canc.2016.217
20. Zhang S-Y, Song X-Y, Li Y, Ye L-L, Zhou Q, Yang W-B. Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy. Pharmacol Res (2020) 161:105111. doi: 10.1016/j.phrs.2020.105111
21. Moisan F, Francisco EB, Bronovic A, Duran GE, Wang YC, Chaturvedi S, et al. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. Mol Oncol (2014) 8(7):1231-9. doi: 10.1016/j.molonc.2014.03.016
22. Zeng Y, Li B, Liang Y, Reeves PM, Qu X, Ran C, et al. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolong survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. PASEB J (2019) 5(3):6596–608. doi: 10.1007/s100260/17
23. Lu X, Meng T. Depletion of tumor-associated macrophages enhances the anti-tumor effect of doxetaxil in a murine epithelial ovarian cancer. Immunobiology (2019) 224(3):355–61. doi: 10.1016/j.imbio.2019.03.002
24. D’Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique anti-tumor effect of docetaxel in a murine epithelial ovarian cancer. Mol Oncol (2019) 13(7):2088-2097. doi: 10.1007/s12085-019-0826-3
25. Carroll MJ, Kapur A, Felder M, Patankar MS, Kreiger PK. M2 macrophages induce ovarian cancer cell proliferation via a hepargin binding epidermal growth factor/matrix metallocrproteinase 9 intercellular feedback loop. Oncotarget (2016) 7(52):86608–20. doi: 10.18632/oncotarget.13474
26. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa b and JNK. J Immunol (2005) 175(2):1197–205. doi: 10.4049/jimmunol.1517.21197
27. Carroll MJ, Kapur A, Felder M, Patankar MS, Kreiger PK. M2 macrophages induce ovarian cancer cell proliferation via a hepargin binding epidermal growth factor/matrix metallocrproteinase 9 intercellular feedback loop. Oncotarget (2016) 7(52):86608–20. doi: 10.18632/oncotarget.13474
28. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa b and JNK. J Immunol (2005) 175(2):1197–205. doi: 10.4049/jimmunol.1517.21197
29. Carroll MJ, Kapur A, Felder M, Patankar MS, Kreiger PK. M2 macrophages induce ovarian cancer cell proliferation via a hepargin binding epidermal growth factor/matrix metallocrproteinase 9 intercellular feedback loop. Oncotarget (2016) 7(52):86608–20. doi: 10.18632/oncotarget.13474
29. Carroll MJ, Kapur A, Felder M, Patankar MS, Kreiger PK. M2 macrophages induce ovarian cancer cell proliferation via a hepargin binding epidermal growth factor/matrix metallocrproteinase 9 intercellular feedback loop. Oncotarget (2016) 7(52):86608–20. doi: 10.18632/oncotarget.13474
29. Carroll MJ, Kapur A, Felder M, Patankar MS, Kreiger PK. M2 macrophages induce ovarian cancer cell proliferation via a hepargin binding epidermal growth factor/matrix metallocrproteinase 9 intercellular feedback loop. Oncotarget (2016) 7(52):86608–20. doi: 10.18632/oncotarget.13474
29. Carroll MJ, Kapur A, Felder M, Patankar MS, Kreiger PK. M2 macrophages induce ovarian cancer cell proliferation via a hepargin binding epidermal growth factor/matrix metallocrproteinase 9 intercellular feedback loop. Oncotarget (2016) 7(52):86608–20. doi: 10.18632/oncotarget.13474
29. Carroll MJ, Kapur A, Felder M, Patankar MS, Kreiger PK. M2 macrophages induce ovarian cancer cell proliferation via a hepargin binding epidermal growth factor/matrix metallocrproteinase 9 intercellular feedback loop. Oncotarget (2016) 7(52):86608–20. doi: 10.18632/oncotarget.13474
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes infiltration of T cells. Front Immunol (2010) 185(6):3190–8. doi:10.3389/fimmu.2010.00319

Wang et al. 10.3389/fimmu.2010.00319

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) is a common denominator approach to cancer therapy. Cancer Cell (2015) 27(4):450–61. doi:10.1016/j.ccell.2015.03.001

Coukos G, Tanyi J, Kandalaft LE. Opportunities in immunotherapy of ovarian cancer. Ann Oncol (2016) 27 Suppl 1:S1–S9. doi:10.1093/annonc/mdw084

Iwai Y, Ishida M, Tanaka Y, Ozaikazi T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 99(19):12293–9. doi:10.1073/pnas.9945394

Drakes ML, Still PJ. Regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment. Cancers (Basel) (2018) 10(9):920. doi:10.3390/cancers10090930

Uppendahl LD, Dahl CM, Miller JS, Felices M, Geller MA. Natural killer cell-based immunotherapy in gynecologic malignancy: A review. Front Immunol (2017) 8:1825. doi:10.3389/fimmu.2017.01825

Neresian S, Glazerbrook H, Toolanly I, Grantham SB, Boreljeau DR. Naturally killing the silent killer: NK cell-based immunotherapy for ovarian cancer. Front Immunol (2019) 10:1782. doi:10.3389/fimmu.2019.01782

Wortzfeld T, Pogge von Strandmann E, Huber M, Adhikary T, Wagner U, Retzstatt S, et al. The unique molecular and cellular microenvironment of ovarian cancer. Front Oncol (2019) 10:1784. doi:10.3389/fonc.2019.00178

Pescie S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1. A phenotypic and functional characterization. J Allergy Clin Immunol (2019) 133(1):35–46. doi:10.1016/j.jaci.2018.04.025

Li T, Yang Y, Hua X, Wang G, Liu W, Ji C, et al. Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. Cancer Lett (2012) 318(1):154–61. doi:10.1016/j.canlet.2011.12.020

Greppi M, Tabellini G, Patrini O, Candiani S, Decensi A, Parolini S, et al. Strengthening the Anti-Tumor NK cell function for the treatment of ovarian cancer. Int J Mol Sci (2019) 20(4):890. doi:10.3390/ijms20040890

Pillet A-H, Baguati F, Thèze J, Chalabartia LA, Rose T. A programmed switch from IL-15 to IL-2-dependent activation in human NK cells. J Immunol (2009) 182(10):6267–77. doi:10.4049/jimmunol.0803933

Silva RD, Yoshida A, Cardozo D, Jales R, Paust S, Derchain S, et al. Natural killer cell response to IL-2 stimulation is distinct between ascites with the presence or absence of malignant cells in ovarian cancer patients. Int J Mol Sci (2017) 18(3):856. doi:10.3390/ijms18030856

Manita-Smaldone GM, Cerr B, Chu CS. Immunotherapy in ovarian cancer. Hum Vaccines Immunother (2012) 8(9):1179–89. doi:10.4161/hv.20738

Chan CJ, Martinet L, Gilliland S, Souza-Fonseca-Guimaraes F, Chow MT, Towne L, et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol (2014) 15(5):431–8. doi:10.1038/ni.2850

Constantino J, Gomes C, Falcão A, Neves BM, Cruz MT. Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol Res (2017) 65(4):798–810. doi:10.1007/s12026-017-8931-1

Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Front Immunol (2013) 4:438. doi:10.3389/fimmu.2013.00438

Sahabi RA, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res (2017) 27(1):174–95. doi:10.1038/cr.2016.157

Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest (2018) 128(2):805–15. doi:10.1172/JCI96113

Motta JM, Rumjanek VM. Sensitivity of dendritic cells to microenvironment signals. J Immunol (2016) 196(8):473607. doi:10.4049/jimmunol.1600707

Bastien JP, Minguy A, Dave V, Rose T. Cell membrane expression of mPD-L2 in patients with cellular and solid malignancies. Clin Cancer Res (2017) 23(13):3269–76. doi:10.1158/1078-0432.CCR-16-2272
86. Butterfield LH. Dendritic cells in cancer immunotherapy clinical trials: are we making progress? *Front in Immunol* (2013) 4:454. doi: 10.3389/fimmu.2013.00454

87. Bol FK, Schreibelt G, Gerritsen WR, de Vries IJM, Fidgter CG. Dendritic cell-based immunotherapy: state of the art and beyond. *Clin Cancer Res* (2016) 22(8):1897–908. doi: 10.1158/1078-0432.CCR-15-1399

88. Fles DR, Higuchi T, Harris JC, Iba V, Gimotty PA, Adams SF. Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103+ dendritic cells in late-stage ovarian cancer. *Oncoimmunology* (2016) 5(8): e1185583. doi: 10.2124/onci.2016.1185583

89. van Gulik M, Dammeijer F, Aerts JGVM, Vroman H. Combination strategies to optimize efficacy of dendritic cell-based immunotherapy. *Front in Immunol* (2018) 9. doi: 10.3389/fimmu.2018.02759

90. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. *Cell Cycle (Gextown, Tex)* (2006) 5(15):1597–601. doi: 10.4161/cc.5.15.11532

91. Desbois M, Wang Y. Cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironment. *Immunol Rev* (2021) 302(1):241–58. doi: 10.1111/imr.12982

92. Erez N, Glanz S, Rae Y, Avivi C, Barshack I. Cancer-associated fibroblasts express pro-inflammatory factors in human breast and ovarian tumors. *Biochem Biophys Res Commun* (2013) 437(3):397–402. doi: 10.1016/j.bbrc.2013.06.089

93. Yeung T-L, Leung CS, Li F, Wong SST, Mok SC. Targeting stromal-cancer cell crosstalk networks in ovarian cancer treatment. *Biomolecules* (2021) 6(1):3. doi: 10.3390/biom6010003

94. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, et al. TGF-β signaling in fibroblasts modulates the oncosgenic potential of adjacent epithelia. *Science (New York, NY)* (2004) 303(5659):848–51. doi: 10.1126/science.1090922

95. Jiang Y, Wang C, Zhou S. Targeting tumor microenvironment in ovarian cancer: Premise and promise. *Biochem and Biophysics Acta Rev on Cancer* (2020) 1873(2):188361. doi: 10.1016/j.bbcan.2020.188361

96. Deying W, Feng G, Shumei L, Hui Z, Hongqing W. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signaling in ovarian cancer cells. *Biostat Rev* (2017) 37(2):8. doi: 10.4236/rsb.20160470

97. Dasari S, Fang Y, Mitra AK. Cancer associated fibroblasts: Naughty neighbors that drive ovarian cancer progression. *Cancers* (2018) 10(11):406. doi: 10.3390/cancers1011406

98. Najafi M, Farhood B, Mortazavi E. Extracellular matrix (ECM) stiffness and degradation as cancer drivers. *J Cell Biochem* (2019) 120(3):2782–90. doi: 10.1002/jcb.27681

99. Leung CS, Yeung T-L, Yap K-P, Wong K-K, Ho SY. Cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironment. *Immunol Rev* (2021) 302(1):241–58. doi: 10.1111/imr.12982

100. Yamamura S, Matsumura N, Mandai M, Huang Z, Oura T, Baba T, et al. Epigenetic aberrations in ovarian cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironment. *World J Stem Cells* (2015) 7(2):253–65. doi: 10.4232/wjst.v7.i2.255

101. Matei D, Chang DD, Jeng M-H. Imatinib mesylate (Gleevec) inhibits angiogenesis in ovarian cancer cells. *Cancers* (2012) 3(2):617–29. doi: 10.3390/cancers3020617

102. Xiong Y, McDonald LT, Russell DL, Kelly RR, Wilson KR, Mehrotra M, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. *Int J Cancer* (2014) 32(30):3374–84. doi: 10.1002/ijc.25961

103. Lim D, De V, Kwon BS, Chang W, Lee M-S, Kim J, et al. Angiogenesis and vasculogenesis underlie the immune microenvironment in ovarian cancer. *BMB Rep* (2020) 53(6):291–8. doi: 10.5483/BMBRep.2020.53.6.060

104. Monk BJ, Minion LE, Coleman RL. Anti-angiogenic agents in ovarian cancer: past, present, and future. *Ann Oncol* (2016) 27(Suppl 1):s133–49. doi: 10.1093/annonc/mdw993

105. Rossi L, Verrico M, Zaccarelli E, Papa A, Colonna M, Strudel M, et al. Bevacizumab in ovarian cancer: A critical review of phase III studies. *Oncotarget* (2017) 8(7):12839–405. doi: 10.18632/oncotarget.13310

106. Ledermann JA, Emberton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* (2016) 387(10023):1066–74. doi: 10.1016/S0140-6736(15)01167-8

107. du Bois R, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. *J Clin Oncol* (2014) 32(30):3374–84. doi: 10.1200/JCO.2013.55.7348

108. Monk BJ, Poveda A, Vergote I, Rasplagies F, Fujisawa K, Dae B-S, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRIVONA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. *Lancet Oncol* (2014) 15(8):799–808. doi: 10.1016/S1470-2045(14)70244-X

109. Homicko K, Duraisamy J, Doughy M-A, Couloux G. Combine and conquer: Double CTLA-4 and PD-1 blockade combined with whole tumor antigen vaccine cooperate to eradicate tumors. *Cancer Res* (2016) 76(23):7675–67. doi: 10.1158/0008-5472.CAN-16-2868

110. Zamarin D, Burger RA, Sill MW, Powell DJ, Lankes HA, Feldman MD, et al. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: An NRg oncology study. *J Clin Oncol* (2020) 38(16):1814–23. doi: 10.1200/JCO.2019.02059

111. Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer RA, et al. Targeting TREG2 on tumor-associated macrophages enhances immunotherapy. *Cell Rep* (2021) 37(5):109844. doi: 10.1016/j.celrep.2021.109844

112. Kusmartsev S, Eruslanov E, Kübler H, Tseng T, Sakai Y, Su Z, et al. Oxidative stress regulates expression of VEGFIR in myoid cells link to tumor-induced immune suppression in renal cell carcinoma. *J Immunol* (2008) 181(1):346–53. doi: 10.4049/jimmunol.181.1.346
128. Wallin JJ, Bendell JC, Funke R, Szol M, Korski K, Jones S, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun (2016) 7:12624. doi: 10.1038/ncomms12624

129. Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA, et al. Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: A phase 2 clinical trial. JAMA Oncol (2019) 5(12):1731–8. doi: 10.1001/jamaoncol.2019.3343

130. Vanacker H, Harter P, Labidi-Galy SI, Banerjee S, Ouknin A, Lorusso D, et al. PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. Cancer Treat Rev (2021) 99:102255. doi: 10.1016/j.ctrv.2021.102255

131. Ghisoni E, Imbimbo M, Zimmermann S, Valabrega G. Ovarian cancer immunotherapy: Turning up the heat. Int J Mol Sci (2019) 20(12):2927. doi: 10.3390/ijms2012927

132. Domchek SM, Postel-Vinay S, Im S-A, Park YH, Delord J-P, Italiano A, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): An open-label, multicentre, phase 1/2, basket study. Lancet Oncol (2020) 21(9):1155–64. doi: 10.1016/S1470-2045(20)30324-7

133. Banerjee S, Imbimbo M, Roxburgh P, Kim JW, Kim MH, Plummer R, et al. 529MO phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer. Ann Oncol (2022) 33:S788–S9. doi: 10.1016/j.annonc.2022.07.657